Ipsen Announces Data Presentations for Somatuline(R) Depot (lanreotide) in Gastroenteropancreatic Neuroendocrine Tumors at American Society of Clinical Oncology Annual Meeting
Business Wire - Thu May 14, 8:17AM CDT
Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen (Euronext:IPN; ADR:IPSEY), today announced that abstracts of data regarding Somatuline(R) Depot (lanreotide) Injection 120 mg (referred to as Somatuline(R)) will be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago, Illinois, May 29 - June 2, 2015. The data include a poster discussion of a new subgroup analysis of the Phase III CLARINET(R) study in patients with midgut neuroendocrine tumors (NETs).
Ipsen reports strong sales growth in Q1 2015 and raises guidance for the year
Business Wire - Wed Apr 29, 12:00AM CDT
--Specialty care sales up 14.6%(1)
Active Bio and Ipsen call it quits in prostate cancer
Seeking Alpha - at Seeking Alpha - Thu Apr 16, 7:42AM CDT
Active Biotech and Ipsen Announce Their Decision to Discontinue the Development of tasquinimod in Prostate Cancer
Business Wire - Thu Apr 16, 12:00AM CDT
Regulatory News:
Ipsen Biopharmaceuticals expands to Canada
CNW Group - Wed Apr 15, 7:45AM CDT
International pharmaceutical company opens new headquarters in Ontario
Ipsen and Hannover Medical School Start Joint Research in Recombinant Botulinum Neurotoxins for Targeted Secretion Inhibitors
Business Wire - Wed Apr 08, 1:00AM CDT
Regulatory News:
Ipsen Expands Ties to Harvard University with Signing of a New Research Alliance Agreement
Business Wire - Wed Apr 01, 11:00AM CDT
Regulatory News:
Ipsen inaugurates new Cambridge, MA R&D center, at the heart of the most important biomedical research & innovation hub in the USA, to expand U.S. presence
Business Wire - Wed Apr 01, 6:00AM CDT
Regulatory News:
Ipsen's 2014 Results and 2015 Financial Objectives
Business Wire - Tue Mar 03, 12:00AM CST
--Core diluted EPS of EUR2.22, up 20.3%
Ipsen Announces Third Resupply of Increlex(R) (mecasermin [rDNA origin] Injection) in the U.S. in 2015
Business Wire - Mon Mar 02, 11:00AM CST
--Ipsen continues to work with the FDA to release future batches of Increlex(R)
Dominique Laymand is Appointed as Ipsen's Senior Vice President, Chief Ethics and Compliance Officer
Business Wire - Mon Mar 02, 3:00AM CST
Regulatory News:
DBV Technologies Welcomes Dr. J-P Moreau to its Scientific Advisory Board
GlobeNewswire - Fri Feb 13, 12:46AM CST
DBV Technologies, (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, announced today the appointment of Dr Jacques-Pierre Moreau to its Scientific Advisory Board. Dr. Moreau brings to DBV his unique expertise and knowledge across a wide range of disease areas and will contribute in defining aggressive approaches to potentially extend the use of epicutaneous immunotherapy (EPIT(R)) and Viaskin(R) technology to a wide range of therapeutic opportunities.
RDUS: 46.63 (+0.40), DBVT: 25.32 (-0.20)
Ipsen: Sales in the Fourth Quarter and Full Year 2014
Business Wire - Tue Feb 03, 1:30AM CST
--Specialty care sales up 9.9%(1) in 2014
Ipsen announces topline results of two double-blind phase III studies of Dysport(R) in lower limb spasticity in children and in adults
Business Wire - Tue Feb 03, 12:00AM CST
--Treatment with Dysport(R) at the dose of 1500U statistically significantly improved muscle tone (primary endpoint) in adult patients with lower limb spasticity
Dysport successful in two label expansion studies
Seeking Alpha - at Seeking Alpha - Mon Jan 26, 7:15AM CST
Ipsen Biopharmaceuticals to Present Further Data on Recently FDA-Approved Antitumor Therapy, Somatuline(R) Depot(R) (lanreotide), at Gastrointestinal Cancers Symposium
Business Wire - Tue Jan 13, 7:33AM CST
Ipsen Biopharmaceuticals Inc., an affiliate of Ipsen (Euronext:IPN; ADR:IPSEY) today announced three presentations of lanreotidedata to be shared at the 2015 Gastrointestinal Cancers Symposium, January 15-17, 2015 in San Francisco, CA. One oral and two poster presentations will explore the use of lanreotide in gastrointestinal and pancreatic neuroendocrine tumors (GEP-NETs), including sub analyses of the pivotal Phase III, multinational, randomized, double-blind clinical trial (CLARINET(R)).
FDA clears expanded label for Ipsen's Somatuline Depot
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 6:56AM CST
Ipsen's Somatuline(R) Depot(R) is the First Therapy Approved by the FDA in the United States for the Treatment of Patients with Locally Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumors
Business Wire - Tue Dec 16, 4:00PM CST
--US organization ready for launch in Q1 2015
Ipsen Announces the FDA Approval of Somatuline(R) Depot(R) (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors
Business Wire - Tue Dec 16, 3:45PM CST
Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), today announced that Somatuline(R) Depot(R) (lanreotide) Injection 120 mg (referred to as Somatuline(R)) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients with unresectable, well or moderately differentiated, locally advanced or metastatic disease to improve progression-free survival (PFS).